- Home
- CHRS vs CHN Comparison
CHRS vs CHN Comparison
Compare CHRS & CHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CHN
- Stock Information
- Founded
- CHRS 2010
- CHN 1992
- Country
- CHRS United States
- CHN United States
- Employees
- CHRS N/A
- CHN N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CHN Investment Managers
- Sector
- CHRS Health Care
- CHN Finance
- Exchange
- CHRS Nasdaq
- CHN Nasdaq
- Market Cap
- CHRS 159.2M
- CHN 168.7M
- IPO Year
- CHRS 2014
- CHN N/A
- Fundamental
- Price
- CHRS $1.35
- CHN $18.36
- Analyst Decision
- CHRS Strong Buy
- CHN
- Analyst Count
- CHRS 4
- CHN 0
- Target Price
- CHRS $4.51
- CHN N/A
- AVG Volume (30 Days)
- CHRS 1.2M
- CHN 31.8K
- Earning Date
- CHRS 11-05-2025
- CHN 01-01-0001
- Dividend Yield
- CHRS N/A
- CHN 0.19%
- EPS Growth
- CHRS N/A
- CHN N/A
- EPS
- CHRS 1.55
- CHN N/A
- Revenue
- CHRS $272,209,000.00
- CHN N/A
- Revenue This Year
- CHRS N/A
- CHN N/A
- Revenue Next Year
- CHRS $109.48
- CHN N/A
- P/E Ratio
- CHRS $0.87
- CHN N/A
- Revenue Growth
- CHRS 52.33
- CHN N/A
- 52 Week Low
- CHRS $0.66
- CHN $9.00
- 52 Week High
- CHRS $2.43
- CHN $12.98
- Technical
- Relative Strength Index (RSI)
- CHRS 64.99
- CHN 77.43
- Support Level
- CHRS $1.23
- CHN $17.83
- Resistance Level
- CHRS $1.40
- CHN $18.25
- Average True Range (ATR)
- CHRS 0.08
- CHN 0.31
- MACD
- CHRS -0.00
- CHN 0.05
- Stochastic Oscillator
- CHRS 72.13
- CHN 94.79
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.